WebMar 22, 2024 · PARSIPPANY, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the submission of its supplemental new drug … WebMar 22, 2024 · -- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over –-- Conference call tomorrow at 8:30 a.m. ET -- …
Pacira Announces FDA Approval of Supplemental New Drug …
WebMar 29, 2024 · Pacira has three commercial-stage non-opioid treatments: EXPAREL (R) (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane ... WebPharmaceutical, Biologics, and Medical Device Regulatory Affairs executive offering global and regional expertise gained from progressively senior … people\u0027s united bank worcester
Pacira BioSciences: FDA to Review Exparel in Lower Extremity …
WebOct 5, 2024 · Pacira BioSciences, Inc. PCRX announced that it received a Paragraph IV Certification notice letter, which stated that New Jersey-based eVenus Pharmaceutical Laboratories, Inc. has submitted an... WebMar 23, 2024 · Pacira BioSciences, Inc. PCRX announced that the FDA has approved its supplemental new drug application (sNDA) seeking approval of its long-acting local analgesic, Exparel, for use in children ... WebMar 5, 2024 · Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL ® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April … people\u0027s united bank zoominfo